Reassessing *Escherichia coli* as a cell factory for biofuel production

Chonglong Wang^a, Brian F. Pflieger^{b, c*} and Seon-Won Kim^{d**}

^aSchool of Biology and Basic Medical Sciences, Soochow University, Suzhou, People's Republic of China

^bDepartment of Chemical and Biological Engineering, University of Wisconsin—Madison, Madison, Wisconsin, USA

^cMicrobiology Doctoral Training Program, University of Wisconsin—Madison, Madison, Wisconsin, USA

^dDivision of Applied Life Science (BK21 Plus), PMBBRC, Institute of Agriculture and Life Sciences, Gyeongsang National University, Jinju, Republic of Korea

*Corresponding address: 1415 Engineering Drive, Madison, WI 53706; E-mail: brian.pflieger@wisc.edu

**Corresponding address: 501 Jinju-daero, Jinju 52828, Republic of Korea; E-mail: swkim@gnu.ac.kr

Abstract

Via metabolic engineering, industrial microorganisms have the potential to convert renewable substrates into a wide range of biofuels that can address energy security and environmental challenges associated with current fossil fuels. The user-friendly bacterium, *Escherichia coli*, remains one of the most frequently used hosts for demonstrating production of biofuel candidates including alcohol-, fatty acid- and terpenoid-based biofuels. In this review, we summarize the metabolic pathways for synthesis of these biofuels and assess enabling technologies that assist in regulating biofuel synthesis pathways and rapidly assembling novel *E. coli* strains. These advances maintain *E. coli*'s position as a prominent host for developing cell factories for biofuel production.

Introduction

The development of biofuel-producing microbes is motivated by a desire to find sustainable alternatives to fossil fuels and to reduce the net amount of greenhouse gases released through the combustion of transportation fuels [1,2]. Microbial metabolism has evolved to comprise pathways for synthesizing a variety of metabolites with fuel-compatible properties including linear, branched and cyclic alcohols, alkanes, alkenes, esters and aromatics. Microbes isolated from environmental samples often possess these metabolic pathways for biofuel synthesis [3,4]; however, they rarely synthesize biofuels in the elevated quantities needed for economically-viable processes. That said, there exist several natural isolates that produce relevant quantities of fuels, e.g. efficient fermentation of sugar to ethanol by yeast or to butanol by *Clostridium* species [5], but the probability of identifying a natural isolate capable of producing other advanced biofuels is infinitesimally small. Furthermore, natural hosts rarely possess the complete suite of traits required for commercial biofuel production. Engineering native isolates into robust workhorses often requires overcoming limitations such as low growth rates, limited catabolic capabilities, poor tolerance to substrates, products, and desirable environmental conditions. For this reason, the alternative approach of engineering a model, genetically-tractable host is a common strategy for accessing the repertoire of natural and synthetic biofuel-producing pathways.

With the advent of recombinant DNA technology, harnessing a user-friendly microorganism such as *Escherichia coli* for biofuel production could be an attractive alternative to the natural isolates [6-8]. *E. coli* as a host has several advantages over other industrial microbes for biofuel production (Table 1). The advantages are as follows: i) both aerobic and anaerobic growth using various carbon sources in defined salt media; ii) possession of high growth and metabolic rates; iii) a vast knowledgebase of genetic, metabolic and physiological traits; and

iv) a plethora of genetic tools available for performing metabolic engineering. These benefits encourage metabolic engineers to construct novel pathways to synthesize desired biofuel products in the genetically tractable *E. coli* host. Enormous genomic sequences have been disclosed for new metabolic reactions and are available in public databases, which provides a wealth of gene variants to construct novel and efficient pathways for biofuels production in *E. coli*. In fact, several biofuel candidates with great potential to replace traditional fuels have been investigated for production in *E. coli* over the past two decades. Such an engineering process relies on introduction of one or more genes encoding the enzymes of the pathway, which are orchestrated by tools of systems biology, metabolic engineering, and synthetic biology to effectively convert intracellular metabolites into the target products [9,10]. The pathway enzymes therefore need to be expressed in *E. coli* at a level that provides sufficient pathway activity but prevents wasteful usage of cellular resources needed elsewhere in metabolism. Similar engineering efforts are required to optimize the expression of genes that encode other critical traits, e.g. product tolerance, without reducing flux to biofuel or depleting cellular resources.

Therefore, the essences in development of *E. coli* as a cell factory for biofuel production are the construction of novel biosynthesis pathways, the sophisticated regulation of pathways and cellular metabolism, and the manipulation of host tolerance to biofuel products. Other aspects including breakdown of biomass into usable carbohydrates are beyond the scope of this review and have been discussed elsewhere [11,12]. In this review, we will mainly assess the recent metabolic engineering achievements and enabling technologies, and highlight their great application potential to realize overproduction of biofuels in *E. coli* in the future.

Construction of metabolic pathway leading to biofuels in *E. coli*

Pioneering work on the metabolic engineering for biofuels could be traced back to the import of the ethanogenic pathway of *Zymomonas mobilis* into *E. coli* [13]. Heterologous expression of pyruvate decarboxylase and alcohol dehydrogenase results in conversion of pyruvate to ethanol in *E. coli*. However, ethanol as the first generation biofuel has lower energy density of around 30% than gasoline, and is incompatible with current fuel infrastructure owing to its highly hygroscopic and corrosive drawbacks [14,15]. To circumvent this problem, many ingenious biosynthesis pathways have been developed in *E. coli* to generate a variety of fuel-like molecules from the general metabolites (Fig. 1) [16,17]. Collectively, these Biofuel candidates can be categorized into three types: alcohol-derived (larger than two-carbon), fatty acid-derived, and terpenoid-derived biofuels.

One of the most recognized and promising biofuel candidates is 1-butanol, which is naturally produced from some *Clostridium* species (e.g. *C. acetobutylicum*) via the typical acetone-butanol-ethanol (ABE) fermentation pathway [5,18]. The fermentative butanol synthesis is initiated with acetyl-CoAs, which are catalyzed consecutively by thiolase, 3-hydroxybutyryl-CoA dehydrogenase, crotonase and butyryl-CoA dehydrogenase for synthesis of butyryl-CoA, and finally converted to 1-butanol by aldehyde/alcohol dehydrogenase. This pathway has been reconstructed in *E. coli* by several research groups for non-native production of butanol [19-21]. Amino acid metabolism leads to the synthesis of many interesting small organic acids including α -ketoacids that can be converted to alcohols with promising fuel properties. Production of C₃-C₅ alcohols was demonstrated in *E. coli* using the Ehrlich degradation pathway from yeast; the pathway consists of a promiscuous decarboxylase converting α -ketoacids to aldehydes and a dehydrogenase converting aldehydes to alcohols [22]. Alcohol mixtures including propanol, butanol, isobutanol, and amyl alcohols were produced from the amino acid precursors of various α -ketoacids in *E. coli* [23]. Engineering of enzymes

involved in leucine synthesis pathway enabled recursive elongation of α -ketobutyrate into long-chain α -ketoacids, and resulted in production of longer chain (C₅-C₈) alcohols including pentanol, hexanol, 3-methyl-1-pentanol, 4-methyl-1-pentanol, 4-methyl-1-hexanol and 5-methyl-1-heptanol [24,25]. In addition, overexpression of O-acyltransferase allowed the recombinant *E. coli* to produce various acetate esters using acetyl-CoA as an acyl donor [26]. Other types of esters such as butyrate and isobutyrate esters could be also produced by combination of diverse acyl-CoA synthesis with alcohols production. In addition to serving as a demonstration host for the function of biofuel pathways, *E. coli* has been successfully engineered to increase the performance (TRY: titer, rate, and yield) of alcohol (1-propanol, isopropanol, 1-butanol, isobutanol, etc.) production beyond other species (Table 1). Engineered *E. coli* strains produced isopropanol of 143 g/L, 1-butanol of 30 g/L, and isobutanol of 50.9 g/L, respectively [27-29]. *C. acetobutylicum* as a native butanol producer produced 1-butanol up to 130 g/L [30], but failed in the production of other higher alcohols. *Saccharomyces cerevisiae* was engineered to produce isobutanol at a titer of 1.62 g/L only [31]. *Corynebacterium glutamicum*, a well-known amino acid producer, was also engineered to produce isobutanol based on its effective L-valine synthesis pathway. The productivity obtained from the engineered *C. glutamicum* is 13 g/L of titer, 0.32 g/L/h of rate, and 0.20 g/g glucose of yield, which is however much lower than the productivity (titer, 50.9 g/L; rate, 0.70 g/L/h ; and yield, 0.29 g/g glucose) obtained from an engineered *E. coli* [27,32]. *Bacillus subtilis* was made to produce butanol and isobutanol albeit a quiet low in titer [21,33], but the conversion of protein waste to biofuels was a benefit of using *B. subtilis* [34].

Fatty acids are natural precursors to many classes of compounds found in current fuels (e.g. alcohols, alkanes, and esters) but are more commonly thought of as the main component of naturally occurring lipids, such as phosphoglycerides of cell membrane constituents and

triglycerides of energy storage materials. Biosynthesis of fatty acids is an iterative carbon-chain elongation process using acetyl-CoA as a primer, and malonyl-CoA or methylmalonyl-CoA as extending molecules by type I fatty acid synthase (FAS) in animals and fungi, or type II FAS in most bacteria. Fatty acids can be converted to fatty acid esters by promiscuous acyltransferases, to fatty alcohols by reductase and alkanes by decarboxylases [35-38]. For example, the aldehyde reductase YbbO of *E. coli* has been re-illuminated to reduce fatty aldehyde to fatty alcohol production [38]. The major concern for fatty acid-derived biofuels in terms of fuel properties is to synthesize various fatty acids with different chain lengths or branched chains that alter their physical properties (e.g. cloud point). Chain length can be controlled by thioesterases expressed in many bacteria and plants and the introduction of these thioesterases in *E. coli* enabled production of fatty acids with different chain lengths [39,40]. The 1,4-dihydroxy-2-naphthoyl-CoA thioesterase YdiI of *E. coli* could function as a cycle-terminating enzymes to hydrolyze acyl-CoAs and produce corresponding short- and medium-chain α,β -unsaturated carboxylic acids [41]. The unexpected role of YdiI could be assessed in *E. coli* with an engineered reversal of the β -oxidation. Replacement of a straight chain acyl-CoA-specific β -ketoacyl-ACP synthase (straight FabH) with a branched-chain-acyl-CoA-specific homolog (branch FabH) led to the synthesis of branched chain fatty acids [42]. Complete lipoylation of 2-oxoacid dehydrogenase by engineering of protein lipoylation pathways increased the percentage of the branched chain fatty acids to 77% of total fatty acid production [43]. The fatty acid β -oxidation cycle was reversed to increase the carbon and energy efficiency of acyl-CoAs synthesis by using acetyl-CoA instead of malonyl-CoA for the acyl-chain elongation, which resulted in higher production of fatty alcohols [44]. *E. coli* and *S. cerevisiae* have been engineered to produce fatty alcohols and fatty alkanes, albeit relatively low in the production titers due to a low efficiency of the relevant enzymes. *E. coli* produced 1.95 g/L fatty alcohols and 0.58 g/L fatty alkanes [45,46], whereas *S. cerevisiae*

produced 1.1 g/L of fatty alcohols and 0.1 g/L of fatty alkanes, respectively [47,48]. *E. coli* was superior to *S. cerevisiae* in production of both fatty alcohols and alkanes. Oleaginous microorganisms such as *Yarrowia lipolytica*, which are likely to accumulate lipids in a high content, can be a good host for production of fatty acid-derived biofuels (Table 1) [49,50]. An engineered *Y. lipolytica* expressing acetyl-CoA carboxylase (ACC) and diacylglycerol acyltransferase (DGAT) presented the overall yield of 0.195 g lipids/g glucose, an equivalent to 61% of the theoretical maximum yield [51]. The further overexpression of Δ -9 stearoyl-CoA desaturase (SCD) improved the production yield to 0.234 g/g glucose (85% of the theoretical maximum yield) [52]. However, metabolic engineering of *Y. lipolytica* for fatty acid-derived biofuels is still in its infancy and remains to be developed by more studies [53-56].

Terpenoids are a large family of natural products with great pharmaceutical and nutritional interests. They have been also considered as ideal drop-in biofuel molecules because of their long chain hydrocarbon structure. Biosynthesis of terpenoids is initiated from two universal C₅ units, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which can be condensed by a head-to-tail manner into a series of isoprenyl diphosphate: geranyl diphosphate (GPP, C₁₀), farnesyl diphosphate (FPP, C₁₅) and geranylgeranyl diphosphate (GGPP, C₂₀). Metabolic engineering of mevalonate (MVA) pathway and 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway for the synthesis of IPP and DMAPP has been reviewed elsewhere [57,58]. Terpenoids with simple olefins structure render promising physical and chemical traits as biofuels, which can be produced by simple dephosphorylation of the isoprenyl diphosphate such as IPP, DMAPP, GPP and FPP. As terpene synthases and phosphatases mediating the dephosphorylation serve a critical role in production of terpenoid-derived biofuels, a challenge is to secure an appropriate enzyme from either plants

171 or bacteria converting isoprenyl diphosphates to terpenoid biofuels. Production of
172 isopentenols was reported only from *E. coli*. Screening of *Bacillus subtilis* genomic DNA
173 library revealed the Nudix hydrolase NudF hydrolyzing DMAPP and IPP to prenol and
174 isoprenol [59], which are collectively called isopentenols. The investigation of Nudix
175 (Nucleoside diphosphate linked to X) family members from *E. coli* demonstrated another
176 good candidate, Nudix hydrolase NudB [60]. Both NudF and NudB have been used for
177 isopentenol production in *E. coli*, and 2.23 g/L of isopentenol (70% of apparent theoretical
178 yield) was produced in the engineered *E. coli* overexpressing NudB [61,62]. *E. coli*
179 undecaprenyl diphosphate phosphatases, YbjG and PgpB, have been recently identified to
180 hydrolyze FPP to farnesol, and successfully applied for farnesol production of 526.1 mg/L in
181 a shake flask [63], which was significantly higher than the farnesol production (145.7 mg/L)
182 of *S. cerevisiae* in a bioreactor [64]. Thus, some promiscuous phosphatases have been re-
183 evaluated as important participants in production of terpenoid alcohols. To date, the advances
184 in engineering of terpene synthases have also proceeded production of pinene, geraniol,
185 limonene, farnesene and bisabolene [65-69], although the reported production titers have
186 been limited at a scale of mg/L in a shake flask culture. Terpenoid molecules are promising
187 alternatives to diesel and jet fuels due to their branched hydrocarbon chains and various ring
188 structures, which lower their freezing temperature [68]. However, production of these
189 molecules has required significant effort and successful demonstrations are being reported
190 (e.g. isoprene (C₅, hemiterpene) production in *E. coli* and farnesene (C₁₅, sesquiterpene)
191 production in *S. cerevisiae*) [70,71]. By optimizing fermentation conditions, an engineered *E.*
192 *coli* strain produced more than 60 g/L of isoprene with volumetric productivity of 2 g/L/h,
193 and an engineered *S. cerevisiae* produced more than 100 g/L of farnesene with volumetric
194 productivity of up to 2.24 g/L/h in a bioreactor. The significant production of isoprene and

farnesene encourages us to improve productivity of terpenoid biofuels by a creative engineering of host strains and a fermentation optimization in bioreactor.

New enabling technologies for biofuel production in *E. coli*

To build a synthetic metabolic pathway in *c* one typically collects genes from various organisms and combines them with gene expression signals (e.g. promoter, terminator, ribosome binding site - RBS) in expression vectors. Genes are often selected based on their performance in their native host or in *in vitro* assays. Transplantation of genes between hosts is not always able to recapitulate these advantages. The performance of the heterologous pathway can suffer from incorrect or poor expression of proteins, promiscuous activity of enzymes on substrates not found in the native host, accumulation of toxic intermediates, and cross-talk with native host metabolism. Subcellular localization of certain eukaryotic enzymes of terpenes synthesis is also a challenge in their implementation in *E. coli* owing to lack of organelles in the host. For these reasons, metabolic engineers have developed a wide array of tools for optimizing functional expression of heterologous pathways. Common approaches include re-coding of genes to optimize codon usage, overexpression of rate-determining enzymes, titrating gene expression with plasmid copy number, promoter strength and RBS strength, and screening combinatorial libraries of genes and control elements [72,73]. In addition, numerous synthetic biology techniques have been developed to enhance the rate of strain construction and to increase the complexity of gene regulation [74,75].

The bacteria adaptive immunity system CRISPR (clustered, regularly interspaced, short palindromic repeats) technology provides a powerful genetic tool for genome editing and gene silencing [76,77]. The endonuclease Cas9 with guide RNA (gRNA) can specifically recognizes and cleaves target DNAs, which facilitates generation of mutations, deletions or insertions for engineering of host strain (Fig. 2a). A large DNA fragment encoding an

isobutanol synthesis pathway was effectively integrated into *E. coli* genome by using a Cas9/CRISPR-based one-step approach [78]. A Cas9 mutant, which has lost the endonuclease activity, has been used to block transcriptions through its binding to target genes, which allows a simultaneous repression of multiple genes by using multiple gRNAs (Fig. 2a). Such a CRISPR interference (CRISPRi) technology was used to repress the transcription factor FadR, which resulted in an increase in fatty acid synthesis and a reduction in β -oxidation in *E. coli* [79]. Kim *et al* used the same approach to regulate a heterologous MVA pathway for production of bisabolol as well as to repress a chromosomal *ispA* gene for production of isoprene [80]. Antisense RNAs (asRNAs), which are able to complementarily bind to 5'-untranslated region (5'-UTR) of their cognate transcripts, have been created and applied for precise control of gene expression [81]. The tailored asRNAs targeting *fabB* and *fabF* effectively repressed malonyl-CoA synthesis in *E. coli* [82]. Small regulatory RNAs (sRNAs) can also target their complementary mRNAs, which recruits host factor Hfq and subsequently induce the mRNA degradation [83]. Inspired from this, artificial sRNAs have been designed with the predictable repression efficiency to improve production of tyrosine and 1,3-diamimopropane [84,85].

Prokaryotic *E. coli* allows expression of a synthetic pathway in a single operon, which is convenient for transcriptional control of multi-genes, but ineffective for modulation of expression level of each gene independently. The expression level of each gene in an operon can be modulated by rational design of the ribosomal binding site (RBS) to have a desired translational initiation rate (TIR). *In silico* program is available to guide the RBS design [86], which has been validated in *E. coli* by many examples such as production of geraniol and amorphadiene [73,87]. Single stranded mRNA easily forms secondary structures affecting the translational efficiency, which is worse in lengthy polycistronic transcripts. CRISPR-based

mRNA processing has been developed for physical separation of each cistron to minimize the translational interference due to the formation of secondary structures of polycistronic transcripts [88]. An entire synthetic pathway can also be divided into several modules and the modules are combinatorically combined and modulated to maximize the pathway efficiency, which is called multivariate modular metabolic engineering (MMME) [89]. Besides, the advance of Systems biology is helping us to mitigate bottleneck of the engineered pathway and to understand the complex crosstalk that occurs between the pathway and the native metabolic network. Targeted proteomics via selected-reaction monitoring (SRM) mass spectrometry was used to optimize the amorphadiene synthetic pathway in *E. coli* [90]. A computational tool termed as principal component analysis of proteomics (PCAP) was consequently developed to mine a quantitative data set of targeted proteomics and to guide metabolic engineering for production of limonene and bisabolene [91]. A recent report described a workflow that integrates metabolomics, proteomics and genome-scale models of *E. coli* metabolism to tailor the host to be suitable for biofuel production [92].

Living organisms have evolved bifunctional enzymes such as MvaE with dual roles of acetoacetyl-CoA synthase and HMG-CoA reductase in the MVA pathway of *Enterococcus faecalis* or organized consecutive enzymes of a metabolic pathway in a complex such as pyruvate dehydrogenase complex to reduce intermediate accumulation and improve the pathway efficiency [93,94]. Artificial fusion of FPP synthase and farnesene synthase significantly improved farnesene production through the directed flow of IPP and DMAPP to farnesene [67]. Artificial protein scaffolds could spatially organize pathway enzymes in a desired stoichiometric ratio for optimal metabolic flux in the synthetic pathway. Organization of the MVA pathway by protein scaffolds showed a great promise for mevalonate production [95]. Beyond these static regulation approaches of gene expression, the application of

biosensors opens up a new avenue to dynamic control of metabolic pathways and cellular behaviors. Biosensors have been devised to positively or negatively respond to accumulation of metabolites (Fig. 2b). FPP responsive promoter was screened by comparative transcriptomics of *E. coli* with accumulation and no accumulation of FPP [96]. The FPP responsive promoter-based biosensor could sense the FPP accumulation in cells, which is applied to dynamic regulation of expression of sesquiterpene synthases. The FPP biosensor showed a great advantage over the inducible *trc* promoter for amorphadiene production in *E. coli* by dynamic expressional regulation of amorphadiene synthase in response to FPP accumulation [96]. FadR-based dynamic sensor-regulation system (DSRS) was developed to sense fatty acyl-CoA, which thereby regulated biosynthesis of fatty acid ethyl ester [97]. Malonyl-CoA responsive FapR was rewired to dynamically control acetyl-CoA carboxylase and fatty acid synthase involved in malonyl-CoA generation and consumption, respectively [98].

Another important concern in construction of a synthetic pathway is substrate stereospecificities of the enzyme components. The inappropriate assembly of butanol synthetic pathway disregarding the substrate stereo-specificity of crotonases severely impaired the pathway efficiency, although crotonase homologs have similar kinetic behavior to their preferred 3-hydroxybutyl-CoA stereoisomers [99]. The inherent enzyme mechanism affords a powerful regulatory strategy called kinetic control element or driving forces to improve the efficiency of the entire pathway. The crotonyl-CoA reductase can serve as a regulatory valve to direct butanol synthesis [29,99].

Tolerance engineering of *E. coli* host against biofuels

E. coli is a non-native biofuel strain from the viewpoint to *S. cerevisiae* and *C. acetobutylicum* naturally producing fuel-like ethanol and butanol. Thanks to advances in

291 synthetic biology, *E. coli* can be drastically engineered to produce drop-in biofuels, while the
292 accumulated organic solvents are generally toxic to *E. coli* cells. Many strains such as
293 *Pseudomonas putida* possess their own built-in tolerance mechanisms against toxic organic
294 solvents, whereas *E. coli* is not competent to deal with toxicity of the biofuels produced in it.
295 A prerequisite to create ideal *E. coli* host for biofuel production is the tolerance engineering
296 and development of associated technologies (Fig. 3).

297 Living organisms employ various strategies against cytotoxicity of organic solvents, such as
298 change of membrane composition, activation of stress response genes and expression of
299 efflux pumps, which could be applied to manipulation of *E. coli* against toxic biofuels.
300 Expression of *Geobacillus sp.* thioesterase, which primarily targets unsaturated medium chain
301 length acyl-ACPs, restored a normal membrane lipids saturation level and improved tolerance
302 towards high production of free fatty acids [100]. Overexpression of MarA involved in
303 multiple antibiotic resistances could improve *E. coli* tolerance to geraniol [101], which was
304 probably due to the MarA-mediated regulation of many stress responsible genes and ArcAB
305 efflux pump. Engineering of efflux pump to expel biofuels out of cells would be the most
306 promising strategy to improve host strain tolerance [102]. Several heterologous efflux pumps
307 were evaluated to secrete terpenoid-based biofuels and found to improve biofuels yields
308 [103,104]. The availability of outer membrane protein TolC to its inner membrane partners to
309 form tripartite efflux channel was elucidated to play an important role in the host tolerance to
310 medium-chain (C₄-C₇) alcohols [105]. Through knock-out of the major efflux pump AcrAB,
311 the increased TolC availability to the relevant inner membrane efflux pumps significantly
312 improved the *E. coli* tolerance to medium-chain alcohols including 1-butanol and isopentenol.
313 These rational approaches weigh on prior knowledges on regulator mechanism and efflux
314 pump preference; however, the advances in “Omics” technology provide a random approach

to elucidate new tolerance mechanism and engineering rationales. It is possible to identify the sense mutations accumulated in a long-term adaptive evolution and to intensify the understanding of the physiological response network of cells to biofuels [106-108], which would contribute to tolerance engineering of the host with desired phenotypes.

Transcription initiation factors, the so-called sigma factors, such as RpoD can regulate a set of genes and change global metabolism to combat exotic stresses in *E. coli* [109]. Thus, the engineering of the sigma factors, which is called global transcription machinery engineering (gTME), offers another convenient and efficient method to improve host tolerance, because the sophisticated works of tolerance manipulation can be simplified to the level of engineering a single endogenous transcription factor. The error-prone RCR-based gTME has been developed to improve *E. coli* tolerance to biofuels and exposed several potential engineering targets for further strain improvements [110]. Biofuel tolerance is a complicated multi-genic phenotype involving up-regulation of heat shock proteins, induction of efflux pumps, modifications of cell membrane and envelope, modifications of energy generation and utilization, and other unknown tolerance mechanisms [111,112]. It is difficult to achieve the enhanced biofuel tolerance traits without deep understanding of genetic, metabolic, and physiological characteristics of host strains. Thus, the most of successful engineering work on biofuel tolerance has been reported in *E. coli*.

Conclusions

During the past decade, a diverse array of natural and artificial biofuel synthesis pathways have been demonstrated in the genetically tractable bacterium, *E. coli*. Given the speed with which *E. coli* can be engineered, many demonstrations have advanced to near-commercial levels of biofuel production. While many targets are not yet produced in sufficient quantities, new synthetic and systems biology tools are enabling the creation of sophisticated regulatory

339 and pathway assembly strategies. Similar efforts will be used to enhance other traits critical
340 to industrial biofuel synthesis. In our opinion, these endeavors will keep *E. coli* as a preferred
341 host when developing microbial cell factories for biofuel production

Acknowledgements

This work was supported by C1 Gas Refinery Program through the NRF funded by the MSIP (NRF-2016M3D3A1A01913246 / NRF-2015M3D3A1A01064882), and a grant (NRF-2016M1A2A2924237) from the National Research Foundation, MSIP, Korea and the Gyeongsang National University Fund for Professors on Sabbatical Leave, 2016. Wang C. also thanked a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). Pfleger B. F. is supported by grants from the US Department of Energy (DE-SC0010329), National Science Foundation (CBET 1149678; EFRI-1240268), and the William F. Vilas Trust.

Reference

Articles of particular interest, published within the period of review, have been highlighted as:

* of special interest

** of outstanding interest

1. Rude MA, Schirmer A: **New microbial fuels: a biotech perspective.** *Curr Opin Microbiol* 2009, **12**:274-281.
2. Fortman JL, Chhabra S, Mukhopadhyay A, Chou H, Lee TS, Steen E, Keasling JD: **Biofuel alternatives to ethanol: pumping the microbial well.** *Trends Biotechnol* 2008, **26**:375-381.
3. Dugar D, Stephanopoulos G: **Relative potential of biosynthetic pathways for biofuels and bio-based products.** *Nat Biotechnol* 2011, **29**:1074-1078.
4. Huffer S, Roche CM, Blanch HW, Clark DS: ***Escherichia coli* for biofuel production: bridging the gap from promise to practice.** *Trends Biotechnol* 2012, **30**:538-545.

- 364 5. Ezeji TC, Qureshi N, Blaschek HP: **Bioproduction of butanol from biomass: from genes**
365 **to bioreactors.** *Curr Opin Biotechnol* 2007, **18**:220-227.
- 366 6. Alper H, Stephanopoulos G: **Engineering for biofuels: exploiting innate microbial**
367 **capacity or importing biosynthetic potential?** *Nat Rev Microbiol* 2009, **7**:715-723.
- 368 7. Atsumi S, Liao JC: **Metabolic engineering for advanced biofuels production from**
369 ***Escherichia coli*.** *Curr Opin Biotechnol* 2008, **19**:414-419.
- 370 8. Chen X, Zhou L, Tian K, Kumar A, Singh S, Prior BA, Wang Z: **Metabolic engineering of**
371 ***Escherichia coli*: a sustainable industrial platform for bio-based chemical**
372 **production.** *Biotechnol Adv* 2013, **31**:1200-1223.
- 373 9. Bhan N, Xu P, Koffas MA: **Pathway and protein engineering approaches to produce**
374 **novel and commodity small molecules.** *Curr Opin Biotechnol* 2013, **24**:1137-1143.
- 375 10. Yadav VG, De Mey M, Lim CG, Ajikumar PK, Stephanopoulos G: **The future of**
376 **metabolic engineering and synthetic biology: towards a systematic practice.**
377 *Metab Eng* 2012, **14**:233-241.
- 378 11. Merino ST, Cherry J: **Progress and challenges in enzyme development for biomass**
379 **utilization.** *Adv Biochem Eng Biotechnol* 2007, **108**:95-120.
- 380 12. Weng JK, Li X, Bonawitz ND, Chapple C: **Emerging strategies of lignin engineering**
381 **and degradation for cellulosic biofuel production.** *Curr Opin Biotechnol* 2008,
382 **19**:166-172.
- 383 13. Ingram LO, Conway T, Alterthum F: **Ethanol production by *Escherichia coli* strains**
384 **co-expressing *Zymomonas* PDC and ADH genes.** US Patent 1991.
- 385 14. Lee SK, Chou H, Ham TS, Lee TS, Keasling JD: **Metabolic engineering of**
386 **microorganisms for biofuels production: from bugs to synthetic biology to fuels.**
387 *Curr Opin Biotechnol* 2008, **19**:556-563.

- 388 15. Keasling JD, Chou H: **Metabolic engineering delivers next-generation biofuels.** *Nat*
389 *Biotechnol* 2008, **26**:298-299.
- 390 16. Zhang F, Rodriguez S, Keasling JD: **Metabolic engineering of microbial pathways for**
391 **advanced biofuels production.** *Curr Opin Biotechnol* 2011, **22**:775-783.
- 392 17. Wen M, Bond-Watts BB, Chang MC: **Production of advanced biofuels in engineered *E.***
393 ***coli*.** *Curr Opin Chem Biol* 2013, **17**:472-479.
- 394 18. Xue C, Zhao XQ, Liu CG, Chen LJ, Bai FW: **Prospective and development of butanol**
395 **as an advanced biofuel.** *Biotechnol Adv* 2013, **31**:1575-1584.
- 396 19. Atsumi S, Cann AF, Connor MR, Shen CR, Smith KM, Brynildsen MP, Chou KJ, Hanai T,
397 Liao JC: **Metabolic engineering of *Escherichia coli* for 1-butanol production.**
398 *Metab Eng* 2008, **10**:305-311.
- 399 20. Inui M, Suda M, Kimura S, Yasuda K, Suzuki H, Toda H, Yamamoto S, Okino S, Suzuki
400 N, Yukawa H: **Expression of *Clostridium acetobutylicum* butanol synthetic genes**
401 **in *Escherichia coli*.** *Appl Microbiol Biotechnol* 2008, **77**:1305-1316.
- 402 21. Nielsen DR, Leonard E, Yoon SH, Tseng HC, Yuan C, Prather KL: **Engineering**
403 **alternative butanol production platforms in heterologous bacteria.** *Metab Eng*
404 2009, **11**:262-273.
- 405 22. Hazelwood LA, Daran JM, van Maris AJ, Pronk JT, Dickinson JR: **The Ehrlich pathway**
406 **for fusel alcohol production: a century of research on *Saccharomyces cerevisiae***
407 **metabolism.** *Appl Environ Microbiol* 2008, **74**:2259-2266.
- 408 23. Atsumi S, Hanai T, Liao JC: **Non-fermentative pathways for synthesis of branched-**
409 **chain higher alcohols as biofuels.** *Nature* 2008, **451**:86-89.
- 410 24. Zhang K, Sawaya MR, Eisenberg DS, Liao JC: **Expanding metabolism for biosynthesis**
411 **of nonnatural alcohols.** *Proc Natl Acad Sci U S A* 2008, **105**:20653-20658.

25. Marcheschi RJ, Li H, Zhang K, Noey EL, Kim S, Chaubey A, Houk KN, Liao JC: **A synthetic recursive "+1" pathway for carbon chain elongation.** *ACS Chem Biol* 2012, **7**:689-697.
26. Rodriguez GM, Tashiro Y, Atsumi S: **Expanding ester biosynthesis in *Escherichia coli*** *Nat Chem Biol* 2014, **10**:259-265.
27. Baez A, Cho KM, Liao JC: **High-flux isobutanol production using engineered *Escherichia coli*: a bioreactor study with *in situ* product removal.** *Appl Microbiol Biotechnol* 2011, **90**:1681-1690.
28. Inokuma K, Liao JC, Okamoto M, Hanai T: **Improvement of isopropanol production by metabolically engineered *Escherichia coli* using gas stripping.** *J Biosci Bioeng* 2010, **110**:696-701.
29. Shen CR, Lan EI, Dekishima Y, Baez A, Cho KM, Liao JC: **Driving forces enable high-titer anaerobic 1-butanol synthesis in *Escherichia coli*.** *Appl Environ Microbiol* 2011, **77**:2905-2915.
30. Jang YS, Lee JY, Lee J, Park JH, Im JA, Eom MH, Lee J, Lee SH, Song H, Cho JH, et al.: **Enhanced butanol production obtained by reinforcing the direct butanol-forming route in *Clostridium acetobutylicum*.** *MBio* 2012, **3**.
31. Matsuda F, Ishii J, Kondo T, Ida K, Tezuka H, Kondo A: **Increased isobutanol production in *Saccharomyces cerevisiae* by eliminating competing pathways and resolving cofactor imbalance.** *Microb Cell Fact* 2013, **12**:119.
32. Blombach B, Riester T, Wieschalka S, Ziert C, Youn JW, Wendisch VF, Eikmanns BJ: ***Corynebacterium glutamicum* tailored for efficient isobutanol production.** *Appl Environ Microbiol* 2011, **77**:3300-3310.
33. Qi H, Li S, Zhao S, Huang D, Xia M, Wen J: **Model-driven redox pathway manipulation for improved isobutanol production in *Bacillus subtilis***

437 **complemented with experimental validation and metabolic profiling analysis.**

438 *PLoS One* 2014, **9**:e93815.

439 34. Choi KY, Wernick DG, Tat CA, Liao JC: **Consolidated conversion of protein waste into**
440 **biofuels and ammonia using *Bacillus subtilis*.** *Metab Eng* 2014, **23**:53-61.

441 35. Park MO: **New pathway for long-chain n-alkane synthesis via 1-alcohol in *Vibrio***
442 ***furnissii* M1.** *J Bacteriol* 2005, **187**:1426-1429.

443 36. Dennis MW, Kolattukudy PE: **Alkane biosynthesis by decarbonylation of aldehyde**
444 **catalyzed by a microsomal preparation from *Botryococcus braunii*.** *Arch Biochem*
445 *Biophys* 1991, **287**:268-275.

446 37. Yu KO, Jung J, Kim SW, Park CH, Han SO: **Synthesis of FAEEs from glycerol in**
447 **engineered *Saccharomyces cerevisiae* using endogenously produced ethanol by**
448 **heterologous expression of an unspecific bacterial acyltransferase.** *Biotechnol*
449 *Bioeng* 2012, **109**:110-115.

450 *38. Fatma Z, Jawed K, Mattam AJ, Yazdani SS: **Identification of long chain specific**
451 **aldehyde reductase and its use in enhanced fatty alcohol production in *E. coli*.**
452 *Metab Eng* 2016, **37**:35-45.

453 39. Jawed K, Mattam AJ, Fatma Z, Wajid S, Abdin MZ, Yazdani SS: **Engineered production**
454 **of short chain fatty acid in *Escherichia coli* using fatty acid synthesis pathway.**
455 *PLoS One* 2016, **11**:e0160035.

456 40. Jing F, Cantu DC, Tvaruzkova J, Chipman JP, Nikolau BJ, Yandeu-Nelson MD, Reilly
457 PJ: **Phylogenetic and experimental characterization of an acyl-ACP thioesterase**
458 **family reveals significant diversity in enzymatic specificity and activity.** *BMC*
459 *Biochem* 2011, **12**:44.

460 41. Kim S, Cheong S, Gonzalez R: **Engineering *Escherichia coli* for the synthesis of short-**
461 **and medium-chain α,β -unsaturated carboxylic acids.** *Metab Eng* 2016, **36**:90-98.

42. Jiang W, Jiang Y, Bentley GJ, Liu D, Xiao Y, Zhang F: **Enhanced production of branched-chain fatty acids by replacing β -ketoacyl-(acyl-carrier-protein) synthase III (FabH).** *Biotechnol Bioeng* 2015, **112**:1613-1622.
43. Bentley GJ, Jiang W, Guaman LP, Xiao Y, Zhang F: **Engineering *Escherichia coli* to produce branched-chain fatty acids in high percentages.** *Metab Eng* 2016, **38**:148-158.
44. Dellomonaco C, Clomburg JM, Miller EN, Gonzalez R: **Engineered reversal of the beta-oxidation cycle for the synthesis of fuels and chemicals.** *Nature* 2011, **476**:355-359.
- *45. Cao YX, Xiao WH, Liu D, Zhang JL, Ding MZ, Yuan YJ: **Biosynthesis of odd-chain fatty alcohols in *Escherichia coli*.** *Metab Eng* 2015, **29**:113-123.
46. Choi YJ, Lee SY: **Microbial production of short-chain alkanes.** *Nature* 2013, **502**:571-574.
47. Buijs NA, Zhou YJ, Siewers V, Nielsen J: **Long-chain alkane production by the yeast *Saccharomyces cerevisiae*.** *Biotechnol Bioeng* 2015, **112**:1275-1279.
48. Feng X, Lian J, Zhao H: **Metabolic engineering of *Saccharomyces cerevisiae* to improve 1-hexadecanol production.** *Metab Eng* 2015, **27**:10-19.
49. Zhu Q, Jackson EN: **Metabolic engineering of *Yarrowia lipolytica* for industrial applications.** *Curr Opin Biotechnol* 2015, **36**:65-72.
50. Blazeck J, Hill A, Liu L, Knight R, Miller J, Pan A, Otoupal P, Alper HS: **Harnessing *Yarrowia lipolytica* lipogenesis to create a platform for lipid and biofuel production.** *Nat Commun* 2014, **5**:3131.
51. Tai M, Stephanopoulos G: **Engineering the push and pull of lipid biosynthesis in oleaginous yeast *Yarrowia lipolytica* for biofuel production.** *Metab Eng* 2013, **15**:1-9.

52. Qiao K, Imam Abidi SH, Liu H, Zhang H, Chakraborty S, Watson N, Kumaran Ajikumar P, Stephanopoulos G: **Engineering lipid overproduction in the oleaginous yeast *Yarrowia lipolytica*. *Metab Eng* 2015, **29**:56-65.**
53. Rutter CD, Rao CV: **Production of 1-decanol by metabolically engineered *Yarrowia lipolytica*. *Metab Eng* 2016, **38**:139-147.**
54. Blazeck J, Liu L, Knight R, Alper HS: **Heterologous production of pentane in the oleaginous yeast *Yarrowia lipolytica*. *J Biotechnol* 2013, **165**:184-194.**
55. Wang G, Xiong X, Ghogare R, Wang P, Meng Y, Chen S: **Exploring fatty alcohol-producing capability of *Yarrowia lipolytica*. *Biotechnol Biofuels* 2016, **9**:107.**
56. Xu P, Qiao K, Ahn WS, Stephanopoulos G: **Engineering *Yarrowia lipolytica* as a platform for synthesis of drop-in transportation fuels and oleochemicals. *Proc Natl Acad Sci U S A* 2016, **113**:10848-10853.**
57. Mizioroko HM: **Enzymes of the mevalonate pathway of isoprenoid biosynthesis. *Arch Biochem Biophys* 2011, **505**:131-143.**
58. Rohdich F, Kis K, Bacher A, Eisenreich W: **The non-mevalonate pathway of isoprenoids: genes, enzymes and intermediates. *Curr Opin Chem Biol* 2001, **5**:535-540.**
59. Withers ST, Gottlieb SS, Lieu B, Newman JD, Keasling JD: **Identification of isopentenol biosynthetic genes from *Bacillus subtilis* by a screening method based on isoprenoid precursor toxicity. *Appl Environ Microbiol* 2007, **73**:6277-6283.**
60. Chou HH, Keasling JD: **Synthetic pathway for production of five-carbon alcohols from isopentenyl diphosphate. *Appl Environ Microbiol* 2012, **78**:7849-7855.**
- *61. George KW, Thompson MG, Kang A, Baidoo E, Wang G, Chan LJ, Adams PD, Petzold CJ, Keasling JD, Lee TS: **Metabolic engineering for the high-yield production of isoprenoid-based C₅ alcohols in *E. coli*. *Sci Rep* 2015, **5**:11128.**

62. Zheng Y, Liu Q, Li L, Qin W, Yang J, Zhang H, Jiang X, Cheng T, Liu W, Xu X, et al.: **Metabolic engineering of *Escherichia coli* for high-specificity production of isoprenol and prenol as next generation of biofuels.** *Biotechnol Biofuels* 2013, **6**:57.
- *63. Wang C, Park JE, Choi ES, Kim SW: **Farnesol production in *Escherichia coli* through the construction of a farnesol biosynthesis pathway - application of PgpB and YbjG phosphatases.** *Biotechnol J* 2016.
64. Ohto C, Muramatsu M, Obata S, Sakuradani E, Shimizu S: **Overexpression of the gene encoding HMG-CoA reductase in *Saccharomyces cerevisiae* for production of prenol alcohols.** *Appl Microbiol Biotechnol* 2009, **82**:837-845.
65. Sarria S, Wong B, Garcia Martin H, Keasling JD, Peralta-Yahya P: **Microbial synthesis of pinene.** *ACS Synth Biol* 2014, **3**:466-475.
66. Zhou J, Wang C, Yoon SH, Jang HJ, Choi ES, Kim SW: **Engineering *Escherichia coli* for selective geraniol production with minimized endogenous dehydrogenation.** *J Biotechnol* 2014, **169**:42-50.
67. Wang C, Yoon SH, Jang HJ, Chung YR, Kim JY, Choi ES, Kim SW: **Metabolic engineering of *Escherichia coli* for α -farnesene production.** *Metab Eng* 2011, **13**:648-655.
68. Peralta-Yahya PP, Ouellet M, Chan R, Mukhopadhyay A, Keasling JD, Lee TS: **Identification and microbial production of a terpene-based advanced biofuel.** *Nat Commun* 2011, **2**:483.
69. Alonso-Gutierrez J, Chan R, Batth TS, Adams PD, Keasling JD, Petzold CJ, Lee TS: **Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production.** *Metab Eng* 2013, **19**:33-41.
70. Whited GM, Feher FJ, Benko DA, Cervin MA, Chotani GK, McAuliffe JC, LaDuca RJ, Ben-Shoshan EA, Sanford KJ: **Development of a gas-phase bioprocess for**

537 **isoprene-monomer production using metabolic pathway engineering.** *Industrial*
538 *Biotechnology* 2010, **6**:152-163.

539 71. Meadows AL, Hawkins KM, Tsegaye Y, Antipov E, Kim Y, Raetz L, Dahl RH, Tai A,
540 Mahatdejkul-Meadows T, Xu L, et al.: **Rewriting yeast central carbon metabolism**
541 **for industrial isoprenoid production.** *Nature* 2016, **537**:694-697.

542 72. Pflieger BF, Pitera DJ, Smolke CD, Keasling JD: **Combinatorial engineering of**
543 **intergenic regions in operons tunes expression of multiple genes.** *Nat Biotechnol*
544 2006, **24**:1027-1032.

545 73. Nowroozi FF, Baidoo EE, Ermakov S, Redding-Johanson AM, Batth TS, Petzold CJ,
546 Keasling JD: **Metabolic pathway optimization using ribosome binding site**
547 **variants and combinatorial gene assembly.** *Appl Microbiol Biotechnol* 2014,
548 **98**:1567-1581.

549 74. Zhang J, Jensen MK, Keasling JD: **Development of biosensors and their application in**
550 **metabolic engineering.** *Curr Opin Chem Biol* 2015, **28**:1-8.

551 75. Wang Z, Cirino PC: **New and improved tools and methods for enhanced biosynthesis**
552 **of natural products in microorganisms.** *Curr Opin Biotechnol* 2016, **42**:159-168.

553 **76. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA: **RNA-guided editing of bacterial**
554 **genomes using CRISPR-Cas systems.** *Nat Biotechnol* 2013, **31**:233-239.

555 **77. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA:
556 **Repurposing CRISPR as an RNA-guided platform for sequence-specific control**
557 **of gene expression.** *Cell* 2013, **152**:1173-1183.

558 These two articles describe CRISPR systems for genome editing and gene silencing.

559

78. Bassalo MC, Garst AD, Halweg-Edwards AL, Grau WC, Domaille DW, Mutalik VK, Arkin AP, Gill RT: **Rapid and efficient one-step metabolic pathway integration in *E. coli*.** *ACS Synth Biol* 2016, **5**:561-568.
79. Cress BF, Toparlak OD, Guleria S, Lebovich M, Stieglitz JT, Englaender JA, Jones JA, Linhardt RJ, Koffas MA: **CRISPathBrick: modular combinatorial assembly of type II-A CRISPR arrays for dCas9-mediated multiplex transcriptional repression in *E. coli*.** *ACS Synth Biol* 2015, **4**:987-1000.
80. Kim SK, Han GH, Seong W, Kim H, Kim SW, Lee DH, Lee SG: **CRISPR interference-guided balancing of a biosynthetic mevalonate pathway increases terpenoid production.** *Metab Eng* 2016, **38**:228-240.
81. Lybecker M, Zimmermann B, Bilusic I, Tukhtubaeva N, Schroeder R: **The double-stranded transcriptome of *Escherichia coli*.** *Proc Natl Acad Sci U S A* 2014, **111**:3134-3139.
82. Yang Y, Lin Y, Li L, Linhardt RJ, Yan Y: **Regulating malonyl-CoA metabolism via synthetic antisense RNAs for enhanced biosynthesis of natural products.** *Metab Eng* 2015, **29**:217-226.
83. Aiba H: **Mechanism of RNA silencing by Hfq-binding small RNAs.** *Curr Opin Microbiol* 2007, **10**:134-139.
84. Chae TU, Kim WJ, Choi S, Park SJ, Lee SY: **Metabolic engineering of *Escherichia coli* for the production of 1,3-diaminopropane, a three carbon diamine.** *Sci Rep* 2015, **5**:13040.
85. Na D, Yoo SM, Chung H, Park H, Park JH, Lee SY: **Metabolic engineering of *Escherichia coli* using synthetic small regulatory RNAs.** *Nat Biotechnol* 2013, **31**:170-174.

584 86. Salis HM, Mirsky EA, Voigt CA: **Automated design of synthetic ribosome binding**
585 **sites to control protein expression.** *Nat Biotechnol* 2009, **27**:946-950.

586 87. Zhou J, Wang C, Yang L, Choi ES, Kim SW: **Geranyl diphosphate synthase: an**
587 **important regulation point in balancing a recombinant monoterpene pathway in**
588 ***Escherichia coli*.** *Enzyme Microb Technol* 2015, **68**:50-55.

589 88. Qi L, Haurwitz RE, Shao W, Doudna JA, Arkin AP: **RNA processing enables**
590 **predictable programming of gene expression.** *Nat Biotechnol* 2012, **30**:1002-1006.

591 89. Biggs BW, De Paepe B, Santos CN, De Mey M, Kumaran Ajikumar P: **Multivariate**
592 **modular metabolic engineering for pathway and strain optimization.** *Curr Opin*
593 *Biotechnol* 2014, **29**:156-162.

594 90. Redding-Johanson AM, Batth TS, Chan R, Krupa R, Szmids H, Adams PD, Keasling JD,
595 Lee TS, Mukhopadhyay A, Petzold CJ: **Targeted proteomics for metabolic pathway**
596 **optimization: application to terpene production.** *Metab Eng* 2011, **13**:194-203.

597 91. Alonso-Gutierrez J, Kim EM, Batth TS, Cho N, Hu Q, Chan LJ, Petzold CJ, Hillson NJ,
598 Adams PD, Keasling JD, et al.: **Principal component analysis of proteomics (PCAP)**
599 **as a tool to direct metabolic engineering.** *Metab Eng* 2015, **28**:123-133.

600 92. Brunk E, George KW, Alonso-Gutierrez J, Thompson M, Baidoo E, Wang G, Petzold CJ,
601 McCloskey D, Monk J, Yang L, et al.: **Characterizing strain variation in**
602 **engineered *E. coli* using a multi-omics-based workflow.** *Cell Syst* 2016, **2**:335-346.

603 93. Hedl M, Sutherlin A, Wilding EI, Mazzulla M, McDevitt D, Lane P, Burgner JW, 2nd,
604 Lehnbeuter KR, Stauffacher CV, Gwynn MN, et al.: ***Enterococcus faecalis***
605 **acetoacetyl-coenzyme A thiolase/3-hydroxy-3-methylglutaryl-coenzyme A**
606 **reductase, a dual-function protein of isopentenyl diphosphate biosynthesis.** *J*
607 *Bacteriol* 2002, **184**:2116-2122.

94. Izard T, Aevvarsson A, Allen MD, Westphal AH, Perham RN, de Kok A, Hol WG:
**Principles of quasi-equivalence and Euclidean geometry govern the assembly of
cubic and dodecahedral cores of pyruvate dehydrogenase complexes.** *Proc Natl
Acad Sci U S A* 1999, **96**:1240-1245.
95. Dueber JE, Wu GC, Malmirchegini GR, Moon TS, Petzold CJ, Ullal AV, Prather KL,
Keasling JD: **Synthetic protein scaffolds provide modular control over metabolic
flux.** *Nat Biotechnol* 2009, **27**:753-759.
96. Dahl RH, Zhang F, Alonso-Gutierrez J, Baidoo E, Batth TS, Redding-Johanson AM,
Petzold CJ, Mukhopadhyay A, Lee TS, Adams PD, et al.: **Engineering dynamic
pathway regulation using stress-response promoters.** *Nat Biotechnol* 2013,
31:1039-1046.
- **97. Zhang F, Carothers JM, Keasling JD: **Design of a dynamic sensor-regulator system
for production of chemicals and fuels derived from fatty acids.** *Nat Biotechnol*
2012, **30**:354-359.
- This article describes a dynamic sensor to the fatty acid flux.
98. Liu D, Xiao Y, Evans BS, Zhang F: **Negative feedback regulation of fatty acid
production based on a malonyl-CoA sensor-actuator.** *ACS Synth Biol* 2015, **4**:132-
140.
99. Bond-Watts BB, Bellerose RJ, Chang MC: **Enzyme mechanism as a kinetic control
element for designing synthetic biofuel pathways.** *Nat Chem Biol* 2011, **7**:222-227.
100. Lennen RM, Pfleger BF: **Modulating membrane composition alters free fatty acid
tolerance in *Escherichia coli*.** *PLoS One* 2013, **8**:e54031.

101. Shah AA, Wang C, Chung YR, Kim JY, Choi ES, Kim SW: **Enhancement of geraniol resistance of *Escherichia coli* by MarA overexpression.** *J Biosci Bioeng* 2013, **115**:253-258.
102. Jones CM, Hernandez Lozada NJ, Pflieger BF: **Efflux systems in bacteria and their metabolic engineering applications.** *Appl Microbiol Biotechnol* 2015, **99**:9381-9393.
103. Lennen RM, Politz MG, Kruziki MA, Pflieger BF: **Identification of transport proteins involved in free fatty acid efflux in *Escherichia coli*.** *J Bacteriol* 2013, **195**:135-144.
104. Dunlop MJ, Dossani ZY, Szmidt HL, Chu HC, Lee TS, Keasling JD, Hadi MZ, Mukhopadhyay A: **Engineering microbial biofuel tolerance and export using efflux pumps.** *Mol Syst Biol* 2011, **7**:487.
- *105. Wang C, Yang L, Shah AA, Choi ES, Kim SW: **Dynamic interplay of multidrug transporters with TolC for isoprenol tolerance in *Escherichia coli*.** *Sci Rep* 2015, **5**:16505.
106. Si HM, Zhang F, Wu AN, Han RZ, Xu GC, Ni Y: **DNA microarray of global transcription factor mutant reveals membrane-related proteins involved in *n*-butanol tolerance in *Escherichia coli*** *Biotechnol Biofuels* 2016, **9**:114.
107. Brynildsen MP, Liao JC: **An integrated network approach identifies the isobutanol response network of *Escherichia coli*.** *Mol Syst Biol* 2009, **5**:277.
108. Foo JL, Jensen HM, Dahl RH, George K, Keasling JD, Lee TS, Leong S, Mukhopadhyay A: **Improving microbial biogasoline production in *Escherichia coli* using tolerance engineering.** *MBio* 2014, **5**:e01932.
109. Gao X, Jiang L, Zhu L, Xu Q, Xu X, Huang H: **Tailoring of global transcription sigma D factor by random mutagenesis to improve *Escherichia coli* tolerance towards low-pHs.** *J Biotechnol* 2016, **224**:55-63.

110. Zhang F, Qian X, Si H, Xu G, Han R, Ni Y: **Significantly improved solvent tolerance of *Escherichia coli* by global transcription machinery engineering.** *Microb Cell Fact* 2015, **14**:175.
111. Nicolaou SA, Gaida SM, Papoutsakis ET: **A comparative view of metabolite and substrate stress and tolerance in microbial bioprocessing: From biofuels and chemicals, to biocatalysis and bioremediation.** *Metab Eng* 2010, **12**:307-331.
112. Dunlop MJ: **Engineering microbes for tolerance to next-generation biofuels.** *Biotechnol Biofuels* 2011, **4**:32.
113. Smith KM, Cho KM, Liao JC: **Engineering *Corynebacterium glutamicum* for isobutanol production.** *Appl Microbiol Biotechnol* 2010, **87**:1045-1055.
114. Vogt M, Brusseler C, Ooyen JV, Bott M, Marienhagen J: **Production of 2-methyl-1-butanol and 3-methyl-1-butanol in engineered *Corynebacterium glutamicum*.** *Metab Eng* 2016, **38**:436-445.
115. Frohwitter J, Heider SA, Peters-Wendisch P, Beekwilder J, Wendisch VF: **Production of the sesquiterpene (+)-valencene by metabolically engineered *Corynebacterium glutamicum*.** *J Biotechnol* 2014, **191**:205-213.
116. Mi J, Becher D, Lubuta P, Dany S, Tusch K, Schewe H, Buchhaupt M, Schrader J: **De novo production of the monoterpenoid geranic acid by metabolically engineered *Pseudomonas putida*.** *Microb Cell Fact* 2014, **13**:170.
117. Yang X, Nambou K, Wei L, Hua Q: **Heterologous production of α -farnesene in metabolically engineered strains of *Yarrowia lipolytica*.** *Bioresour Technol* 2016, **216**:1040-1048.

679 **Table 1**

Comparison of <i>Escherichia coli</i> with other industrial strains for biofuel synthesis					
Strains	Biofuel types			Available genetic tools	Biofuel tolerance
	Higher alcohols	Fatty acids	Terpenoids		
<i>Escherichia coli</i>	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of many higher alcohols • Titer: 143 g/L isopropanol [27], 50.9 g/L isobutanol [28], 30 g/L 1-butanol [29], etc. 	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of many fatty acid derivatives • Titer: 1.95 g/L fatty alcohols [45], 0.6 g/L fatty alkanes [46], 1.1 g/L fatty ester [97], etc. 	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of many terpenoids via MEP or MVA pathway • Titer: 2.2 g/L isopentenol [61], 0.53 g/L farnesol [63], 1.1 g/L bisabolene [91], > 60 g/L isoprene [69], etc. 	Many	<ul style="list-style-type: none"> • Low tolerance to most biofuels • Many studies on tolerance engineering
<i>Corynebacterium glutamicum</i>	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of few higher alcohols • Titer: 4.0 g/L isobutanol [113], 2.8 g/L 3-methyl-1-butanol, and 0.37 g/L 2-methyl-1-butanol [114] 	<ul style="list-style-type: none"> • Non-native producer 	<ul style="list-style-type: none"> • Non-native producer • Engineered for valencene production via MEP pathway • Titer: 2.4 mg/L valencene [115] 	Not many	<ul style="list-style-type: none"> • Not clear for biofuel tolerance • Few studies on tolerance engineering
<i>Saccharomyces cerevisiae</i>	<ul style="list-style-type: none"> • Native ethanol producer • Engineered for isobutanol production • Titer: 1.62 g/L isobutanol [31] 	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of many fatty acid derivatives • Titer: 0.1 g/L fatty alkanes [47], 1.1 g/L hexadecanol [48], etc. 	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of many terpenoids via MVA pathway • Titer: 0.1 g/L farnesol [64], 1.0 g/L bisabolene [68], >100 g/L farnesene [71], etc. 	Many	<ul style="list-style-type: none"> • High tolerance to ethanol • Not many studies on tolerance engineering

<i>Clostridium acetobutylicum</i>	<ul style="list-style-type: none"> • Native butanol producer • Engineered for high butanol production • Titer: 130 g/L butanol [30] 	<ul style="list-style-type: none"> • Non-native producer 	<ul style="list-style-type: none"> • Non-native producer 	Few	<ul style="list-style-type: none"> • High tolerance to butanol • Not many studies on tolerance engineering
<i>Pseudomonas putida</i>	<ul style="list-style-type: none"> • Non-native producer • Engineered for butanol production • Titer range: 0.12 g/L butanol [21] 	<ul style="list-style-type: none"> • Non-native producer 	<ul style="list-style-type: none"> • Non-native producer • Engineered for geranic acid production via MVA pathway • Titer: 0.19 g/L geranic acid [116] 	Not many	<ul style="list-style-type: none"> • High tolerance to many organic solvents • Few studies on tolerance engineering
<i>Bacillus subtilis</i>	<ul style="list-style-type: none"> • Non-native producer • Engineered for production of few higher alcohols • Titer: 24 mg/L butanol [21] and 6.1 g/L isobutanol [33] 	<ul style="list-style-type: none"> • Non-native producer 	<ul style="list-style-type: none"> • Native isoprene producer • Engineered for isoprene production via MEP pathway 	Not many	<ul style="list-style-type: none"> • Not clear for biofuel tolerance • No study on tolerance engineering
<i>Yarrowia lipolytica</i>	<ul style="list-style-type: none"> • Non-native producer 	<ul style="list-style-type: none"> • Native producer • Engineered for production of fatty acid derivatives • Titer: 0.5 g/L decanol [53], 4.98 mg/L pentane [54], and 0.64 g/L hexadecanol [55] 	<ul style="list-style-type: none"> • Non-native producer • Engineered for α-farnesene production via MVA pathway • Titer: 0.26 g/L α-farnesene [117] 	Not many	<ul style="list-style-type: none"> • Not clear for biofuel tolerance • No study on tolerance engineering

681 **Table 2**

Enzymes involved in metabolic engineering of <i>E. coli</i> for biofuel synthesis		
Pathway Types	Engineered enzymes	Products
Alcohols	Ethanogenesis	Pyruvate decarboxylase; Alcohol dehydrogenase
	Ehrlich degradation	α -Ketoacids decarboxylase; Aldehyde dehydrogenase
	ABE fermentation	Thiolase; 3-Hydroxybutyryl-CoA dehydrogenase; Crotonase; Butyryl-CoA dehydrogenase Aldehyde/alcohol dehydrogenase
Fatty acids	Fatty acid synthesis	Acetyl-CoA carboxylase; Fatty acid synthases (e.g., FabH); Thioesterase; Promiscuous acyltransferase, reductase or decarboxylase
	Reversal of β -oxidation	AtoB (acetyl-CoA acetyltransferase); Aldehyde/alcohol dehydrogenase; Thioesterase; YdiO (acyl-CoA dehydrogenase/enoyl-CoA reductase); FadB (3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase); FadA (3-ketoacyl-CoA thiolase)
Terpenoids	MEP pathway	MEP pathway enzymes Isoprenyl diphosphate synthase Terpene synthases
	MVA pathway	MVA pathway enzymes Isoprenyl diphosphate synthase Terpene synthases Promiscuous phosphatases

Figure legends

Figure 1. Scheme of engineered metabolic pathways to produce candidate biofuels in *E.*

***coli*.** Introduction of the heterologous metabolic pathways (black arrows) enables recombinant *E. coli* to synthesize various candidate biofuels from the central metabolites (gray arrows) of *E. coli*. These candidates were categorized into three types: high alcohols, fatty acids and terpenoids.

Figure 2. Schemes of CRISPR technology for gene editing and silencing (a), and biosensor modes for pathway regulation (b).

Figure 3. Engineering schemes of efflux pump and transcription factor for tolerance improvement. Introduction of biofuel synthesis pathway (pBiofuel) in *E. coli* leads to the accumulation of biofuel products, which would cause cytotoxicity in the host cell (upper panel). An engineered efflux pump transports the biofuel products out of cell to reduce the toxicity, and an engineering of transcription factor can regulate global gene expression of the host to improve the biofuel tolerance (upper panel). In a native biofuel producer (lower panel), the tolerance engineering has been restricted due to a limited information on efflux pump and transcription factor of the host.

699

700

(a)

(b)

701

702

703